title: Effect of antiphospholipid antibodies on beta(2) glycoprotein I-phospholipid Interaction.
abstract: OBJECTIVE
  Beta(2)glycoprotein I (beta(2)GPI) physiologically binds to negatively charged phospholipids (PLs) and is a natural regulator of the coagulation cascade. Thrombotic clinical complications and recurrent fetal loss associated with autoimmune antiphospholipid (aPL) antibodies are thought to be related to their binding to Beta(2)GPI-PL complex and interference with the physiological function of Beta(2)GPI.
  
  
  METHODS
  To investigate the effect of aPL on beta(2)GPI-PL interaction, we studied the binding of biotinylated Beta(2)GPI to cardiolipin (CL) by enzyme-linked immunosorbent assay (ELISA) in the presence and absence of purified aPL immunoglobulin G (IgG) antibodies.
  
  
  RESULTS
  Adding five different aPL IgG antibodies with different levels of aPL activity isolated from the sera of five patients with aPL-associated recurrent fetal death greatly increased the binding of biotinylated beta(2)GPI to CL-coated plates. The optical densities (ODs) were 0.635, 0.890, and 1.265 in the presence of three aPL IgG antibodies, compared to 0.425 in the absence of aPL IgG. In contrast, normal human IgG had no enhancing effect. The OD was 0.480 and 0.425, respectively. The enhancement of beta(2)GPI binding to CL by aPL IgG correlated with the titers of aPL antibodies. The use of phosphate-buffered saline with increasing salt concentrations as a washing buffer for the ELISA resulted in more stable binding of beta(2)GPI to PL in the presence of aPL IgG.
  
  
  CONCLUSIONS
  These findings suggest that the binding of autoimmune aPL antibodies to beta(2)GPI-PL complex results in abnormally tighter interaction between beta(2)GPI and PLs, which may lead to physiological dysfunction of beta(2)GPI as a regulator of coagulation.
authors.affiliation: Department of Medicine, Louisiana State University Medical Center, New Orleans 70112-2822, USA.
authors.forename: A E
authors.initials: AE
authors.lastname: Gharavi
authors.forename: E
authors.initials: E
authors.lastname: Cucurull
authors.forename: H
authors.initials: H
authors.lastname: Tang
authors.forename: R M
authors.initials: RM
authors.lastname: Silver
authors.forename: D W
authors.initials: DW
authors.lastname: Branch
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000276:immunology*; D000911:Antibodies, Monoclonal; D016736:Antiphospholipid Syndrome / Q000276:immunology; D019921:Biotinylation; D002308:Cardiolipins / Q000378:metabolism*; D002712:Chlorides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006023:Glycoproteins / Q000302:isolation & purification / Q000378:metabolism*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D011485:Protein Binding / Q000187:drug effects; D053482:beta 2-Glycoprotein I
chemical_list: D017152:Antibodies, Antiphospholipid; D000911:Antibodies, Monoclonal; D002308:Cardiolipins; D002712:Chlorides; D006023:Glycoproteins; D007074:Immunoglobulin G; D053482:beta 2-Glycoprotein I